ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

ARGX

701

-0.82%↓

SHL.DE

34.58

+0.26%↑

FRE

38.84

-2.92%↓

PHIA

23.42

+0.95%↑

FME

37.3

-4.04%↓

Home・Listă Acțiuni・Sanofi SA

Sanofi SA

Închisă

SectorSănătate

76.89 -0.91

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

76.87

Maxim

78.02

Indicatori cheie
By Trading Economics
Venit	-394M 1.6B
Vânzări	-12B 11B
P/E Medie Sector	18.773 49.701
EPS	1.88
Marjă de profit	14.354
Angajați	74,846
EBITDA	1.5B 2.7B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+24.2% upside

Dividende
By Dow Jones
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-9.6B 89B
Deschiderea anterioară	77.8
Închiderea anterioară	76.89

Sentimentul știrilor

By Acuity

37%

63%

95 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

91.3 / 96.1 Suport & Rezistență

Sanofi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 09:03 UTC

Câștiguri

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 apr. 2026, 05:27 UTC

Câștiguri

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 apr. 2026, 06:12 UTC

Câștiguri

Sanofi Posts Higher Sales Amid Leadership Transition

7 mai 2026, 06:47 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

1 mai 2026, 06:14 UTC

Achiziții, Fuziuni, Preluări

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 mai 2026, 06:13 UTC

Achiziții, Fuziuni, Preluări

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 mai 2026, 06:12 UTC

Achiziții, Fuziuni, Preluări

Santander UK Financed Deal From Existing Cash Resources

1 mai 2026, 06:08 UTC

Achiziții, Fuziuni, Preluări

Santander UK Announced Key Terms of Deal July 2025

1 mai 2026, 06:03 UTC

Achiziții, Fuziuni, Preluări

Santander UK Buys TSB Banking for GBP2.65B

1 mai 2026, 06:02 UTC

Achiziții, Fuziuni, Preluări

Santander UK Buys TSB Banking Group

29 apr. 2026, 12:01 UTC

Câștiguri

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 apr. 2026, 06:27 UTC

Market Talk

Câștiguri

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 apr. 2026, 04:55 UTC

Câștiguri

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 apr. 2026, 04:55 UTC

Câștiguri

Santander 1Q Loan Loss Provisions EUR3.225B

29 apr. 2026, 04:54 UTC

Câștiguri

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 apr. 2026, 04:54 UTC

Câștiguri

Santander 1Q Operating Expenses EUR6.48B

29 apr. 2026, 04:52 UTC

Câștiguri

Santander Backs 2028 View

29 apr. 2026, 04:52 UTC

Câștiguri

Santander Backs 2026 View

29 apr. 2026, 04:52 UTC

Câștiguri

Santander 1Q Underlying RoTE 15.2%

29 apr. 2026, 04:51 UTC

Câștiguri

Santander End-1Q CET1 Ratio 14.4%

29 apr. 2026, 04:51 UTC

Câștiguri

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 apr. 2026, 04:51 UTC

Câștiguri

Santander 1Q Net Interest Income EUR11.02B

29 apr. 2026, 04:50 UTC

Câștiguri

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 apr. 2026, 04:50 UTC

Câștiguri

Santander 1Q Underlying Pft EUR3.56B

29 apr. 2026, 04:49 UTC

Câștiguri

Santander 1Q Net Pft EUR5.455B

29 apr. 2026, 04:49 UTC

Câștiguri

Analysts Saw Santander 1Q Rev EUR15.00B

29 apr. 2026, 04:49 UTC

Câștiguri

Santander 1Q Rev EUR15.14B

27 apr. 2026, 09:32 UTC

Market Talk

Câștiguri

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 apr. 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 apr. 2026, 05:34 UTC

Câștiguri

Sanofi: 2026 Expectations Are at Constant Exchange Rates

Comparație

Modificare preț

Sanofi SA Așteptări

Obiectiv de preț

By TipRanks

24.2% sus

Prognoză pe 12 luni

Medie 95.221 EUR 24.2%

Maxim 107 EUR

Minim 85 EUR

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Sanofi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

91.3 / 96.1Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

95 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.